The Board of Directors
Mr Roy Austin BCom, CA (Chairman - Appointed on 20 July 2011) (Independent Director)
Emeritus Professor Robert Elliott MBBS, MD, FRACP
Dr Bernie Tuch BSc, MBBS (Hons), FRACP and Ph D (Appointed on 20 July 2011)
Mr Robert Willcocks BA, LLM (Independent Director) (Appointed on 29 March 2011)
Mr Laurie Hunter MA (Hons) (Independent Director)
Mr Nicholas Geddes (Company Secretary)
Dr Andrea Grant PhD, BA (Hons) (Managing Director) (Appointed on 16 November 2012)
Management Team
Dr Andrea Grant PhD, BA (Hons) (Chief Executive Officer) (Effective from 16 January 2012) and (MD) (Appointed on 16 November 2012)
Emeritus Professor Robert Elliott MBBS, MD, FRACP (Director, Clinical Research and Innovation)
Dr Paul Tan MB, BS, FRACP (Chief Science and Medical Officer) (Appointed on 10 December 2012)
Mr John Cowan (Head of Finance and Administration)
Mr Peter Hosking (Head of Operations)
Isobel Cooper (Head of Animal Welfare and Facilities)
The Board of Directors
Mr Roy Austin BCom, CA, Chairman (Appointed on 20 July 2011), Independent Director
 |
Mr Austin is a consultant to investment banking firm Northington Partners in New Zealand. He brings considerable commercial depth to the LCT Board with over 25 years' investment transaction experience across multiple sectors including healthcare and biotechnology. His experience includes capital raisings, mergers and acquisitions, IP commercialisation, venture capital and international business development.
Mr Austin is Chairman of New Zealand based Cure Kids, a child health research charitable trust and its commercial biotech venture capital fund, Cure Kids Ventures Limited. He holds a number of other directorships in private companies has a BCom and is a member of the New Zealand Institute of Directors and the New Zealand Institute of Chartered Accountants. Mr Austin became the Acting Chairman of the Board following Dr Macdonald's resignation on 24 June 2011. He was elected Chairman on 20 July 2011. He is the Chair of the Remuneration & Nomination committee and a member of the Audit Risk & Compliance committee. He was appointed to the board on 25 February 2011. |
Emeritus Professor Robert Elliott MBBS, MD, FRACP, Director, Clinical Research and Innovation
 |
Professor Elliott trained as a Paediatrician at Adelaide University. He moved to New Zealand in 1970 to become the Foundation Professor, Director of Paediatrics at The University of Auckland. Professor Elliott co founded LCT. He is an Emeritus Professor of Child Health Research and a world leader in diabetes and autoimmune related research.
In 1999 he was awarded a CNZM (a Companion of the New Zealand Order of Merit) for services to the community. In 2011 he was awarded the prestigious World Class New Zealander (Life Sciences) award. He is on the board of Cure Kids, Wings Trust (a NZ trust for the treatment of alcohol and substance abuse) and patron of the NZ Cystic Fibrosis Foundation. He is a director of Breath Easy Limited, a New Zealand company that is developing a new treatment for cystic fibrosis. He was appointed to the board on 15 January 2004. |
Dr Bernie Tuch BSc, MBBS (Hons), FRACP and Ph D (Appointed on 20 July 2011)
 |
Dr Tuch is currently employed as a senior scientist with CSIRO Australia in a cell transplantation project. He was previously a Professor at the University of New South Wales, where he carried out extensive research in islet xenotransplantation over many decades. He is a director of Sydney Cell Therapy Foundation Pty Limited and is a Specialist Practitioner, Endocrinology, Prince of Wales Private Hospital, Sydney and is affiliated with universities in India and USA.
His experience includes capital raising to support his considerable research team and a large international scientific publication list. He has had previous scientific collaborations with LCT and knows the company's direction intimately. Dr Tuch is a member of the Remuneration & Nomination committee. He was appointed to the board on 20 July 2011. |
Mr Robert Willcocks BA, LLM, Independent Director (Appointed on 29 March 2011)
 |
Robert Willcocks is a senior executive with an extensive legal and business background working in particular with Australian listed public companies. He has Bachelor of Arts and Bachelor of Laws degrees from the Australian National University and a Master of Laws degree from the University of Sydney. Mr Willcocks was a partner with the law firm Stephen Jaques & Stephen (now Mallesons Stephen Jaques) from 1980 until 1994, where he was a member of the Corporate Advisory Group with an emphasis on the mining and oil and gas sectors. As corporate adviser he has undertaken assignments in a range of industry sectors.
Mr Willcocks has been a director and Chairman of a number of Australian Securities Exchange (ASX) listed public companies. He is a director of ASX listed ARC Exploration Limited, and Hong Kong Stock Exchange listed APAC Resources Ltd. He is also chairman and director of Trilogy Funds Management Ltd, a Responsible Entity under Australian law. Mr Willcocks is chairman of the Audit Risk & Compliance committee and a member of the Remuneration & Nomination committee. He was appointed to the board on 29 March 2011. |
Mr Laurie Hunter MA (Hons), Independent Director
 |
Mr Hunter has over 40 years' experience as a stockbroker, investment banker and corporate investor in London, Paris and San Francisco. Laurie was a Member of The Stock Exchange, London, a partner at L. Messel and Co, London, a director of Shearson Lehman Hutton and founder of Hunter Capital. His recent focus has been on investing and providing strategic advice to developing companies.
Mr Hunter currently serves on a number of boards including Madagascar Oil Limited where he is chairman and CEO. Mr Hunter is a member of the Audit Risk & Compliance and Remuneration & Nomination committees. He was appointed to the board on 25 August 2006. |
Mr Nicholas Geddes, Company Secretary
 |
Nick is the principal of Australian Company Secretaries, a company secretarial practice that he formed in 1993. Nick is past President and past Board Chairman of Chartered Secretaries Australia and a former Chairman of the NSW Council of that Institute. His previous experience, as a Chartered Accountant and Company Secretary, includes investment banking and development and venture capital in Europe, Africa the Middle East and Asia. Qualifications: Chartered Accountant (Fellow of Institute of Chartered Accountants in England and Wales) and Fellow of the Institute of Chartered Secretaries (Chartered Secretaries Australia). |
Dr Andrea Grant PhD, BA (Hons), Managing Director (Appointed on 16 November 2012) and CEO (Effective from 16 January 2012)
 |
Dr Grant has over 15 years executive experience in pharmaceutical and biotech companies in Europe, USA and New Zealand. She has both a BA Hons in Biochemistry and a PhD in Neuroscience from Cambridge University in the UK. Following her PhD she joined the R&D division of GlaxoSmithKline (UK) where her she was responsible for research and development of novel drug targets for treatment of neurological disorders including Alzheimer's, epilepsy and Parkinson's. In 1999, Andrea joined Incyte (Nasdaq:INCY) as Commercial Director, Northern Europe. Following this, Dr Grant served as Business Director and then Managing Director at biotechnology company Galapagos NV (Euronext:GLPG). In both her roles at Incyte and Galapagos Andrea was successful at securing numerous high value research and licensing partnerships with global pharmaceutical partners.
Andrea immigrated to New Zealand in 2005 and took up the post of General Manger, The Peoples Centre Trust a primary healthcare provider in central Auckland. She then joined Roche Products (NZ) as Public Policy Manager, where she was responsible for government relations and corporate communications. Andrea held Board positions at The Peoples Centre Trust and Youth Mentoring Trust. Hence, together with her overseas commercial and operational management exposure, Andrea brings significant leadership and governance experience in the Australian and New Zealand government, health and biotech sectors. Andrea started as CEO on 16 January 2012 and is appointed as Managing Director on 16 November 2012. |
Management Team
Dr Paul Tan MB, BS, FRACP (Chief Science and Medical Officer) (Appointed on 10 December 2012)
 |
Dr Tan serves as the Chair of the Board of Directors of NZBIO, the New Zealand industry association for bioscience.
Dr Tan joined LCT as managing director of LCT New Zealand in 2004, and served the company as chief executive officer from 2008-2010. His major accomplishments include taking DIABECELLR, the world's first animal to human cell therapy programme, to regulatory approval for clinical trials under international guidelines, developing the designated pathogen-free pig facility suitable for human therapeutics under international guidelines. Dr Tan also initiated several strategic commercial alliances and created significant international peer and governmental support for LCT. Dr Tan stepped down from his role at LCT in 2010 to work as an independent consultant to several biotechnology companies in New Zealand, including LCT. Before this Dr Tan was CEO of CenTec Limited, a biotech company spun off from Centenary Institute for Cancer and Cell Biology, affiliated to the University of Sydney, from 2002-2004. Dr Tan was founding Deputy Director and Head of Health Research at Genesis Research and Development Corporation from 1994-2002, where he managed the intellectual property and patent filings and the clinical trial programme. Prior to his career in the biotechnology industry Dr Tan was Associate Professor of Immunology at The University of Auckland and rheumatology consultant at Auckland Hospital. He graduated from the University of Singapore and undertook postgraduate training at the University of Toronto. |
Mr John Cowan, Head of Finance and Administration
 |
Mr Cowan has over 30 years experience in senior finance positions in publicly listed companies with international operations and public benefit entities. He was Head Finance & Facilities at Auckland War Memorial Museum, CFO at the University of Auckland, Company Secretary at Mair Astley Limited and held senior finance positions in the Goodman Fielder Wattie Group.
He holds a BCA from Victoria University of Wellington and is a Fellow of the New Zealand Institute of Chartered Accountants. |
Mr Peter Hosking, Head of Operations
 |
Mr Hosking has a wealth of relevant skills and experience in the biotech sector. He has held senior Quality Assurance and Operations Management positions at ICPbio (NZ), Nufarm Health & Sciences (NZ), Pfizer (USA & UK) and Glaxo UK. Peter holds a B.Tech degree from Massey University and an MBA from the University of North Carolina. He is a past president of the New Zealand Biotechnology Association. |
Isobel Cooper, Head of Animal Welfare and Facilities
 |
Isobel Cooper is a Fellow of the Institute of Animal Technology UK (NZQA BSc) with over 30 years' experience in managing teams of animal technicians dedicated to caring for animals in breeding and research facilities.
In the UK Isobel worked for Glaxo Smith Kline (GSK) for nearly 20 years. During her years at GSK Isobel managed breeding and research animal facilities with a large team of dedicated staff. Isobel was also part of the project team for the design and build of several new and refurbished animal facilities ranging from 3M GBP to over 50M GBP. In 1998 Isobel immigrated to New Zealand and worked for Genesis Research and Development Corporation Ltd as the company Facilities Manager. Isobel joined Living Cell Technologies in March 2004 to manage all the animal facilities. Since joining LCT Isobel has designed and built a pig breeding facility near Auckland and a large $2.5M sterile barrier pig breeding facility near Invercargill. |
updated 10th December, 2012
| © Copyright 1996-2013 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |